| News
Resistell closes successful financing round
11.12.2018
Resistell has closed on oversubscribed seed financing round. The Basel-based startup is developing an antibiotic susceptibility test that is much faster than conventional tests.
Around 700,000 people die every year due to drug resistant infections. Resistell AG, a spin-off of the École polytechnique fédérale de Lausanne (EPFL), is developing a diagnostic device that can quickly and reliably test patients for antibiotic susceptibility and thus reduce the spreading of antibiotic resistance, according to a press release from the Occident Group. The investment company from Zug participated in Resistell’s seed financing round, together with Hemex AG and six private investors.
Resistell’s diagnostic device uses nanotechnology and Atomic Force Microscopy-based techniques to capture the movements of living bacteria. If an effective antibiotic is applied, the bacteria dies and their movements cease. Unlike conventional tests that take days to complete, the Resistell method delivers accurate results in just hours, allowing patients to be treated with the right medication from day one.
Founded in Basel in April 2018, Resistell was awarded a European patent for the device and method in summer 2018, making Resistell “perfectly placed to raise the funds needed for the next development stage”. Resistell will now move to new premises in Muttenz in the canton of Basel-Landschaft.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
docdok.health involved in coronavirus research project
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.
Read More
Celonic agrees cooperation to combat coronavirus
The Basel-based biopharmaceutical company Celonic Group has agreed a partnership with Airway Therapeutics from the USA. Together, the two companies are planning to develop a drug to treat coronavirus.
Read More
Idorsia receives payment of 45 million US dollars
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..
Read More
Humard robot disinfects using UV light
Humard has developed a robot that can disinfect spaces using UV light. For this, the system manufacturer from the canton of Jura has adapted a mobile industrial robot that is otherwise used in warehouse logistics.
Read More
Roche authorized to distribute coronavirus antibody tests
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.
Read More
Basel is the most popular Swiss location for headquarters
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.
Read More
Healthtech sector growing rapidly in the Basel Area
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.
Read More
Support program has roots in Basel
The online program Selfapy supports people suffering from mental health conditions during the coronavirus lockdown. BaselArea.swiss has provided startup help by way of its DayOne initiative.
Read More
University Hospital Basel treats coronavirus patients with plasma
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.
Read More
Botnar Research Center advancing research into coronavirus
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.
Read More
